Research Papers: Gerotarget (Focus on Aging):

Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM

Liana Spazzafumo, Emanuela Mensà, Giulia Matacchione, Tiziana Galeazzi, Lucia Zampini, Rina Recchioni, Fiorella Marcheselli, Francesco Prattichizzo, Roberto Testa, Roberto Antonicelli, Paolo Garagnani, Massimo Boemi, Massimiliano Bonafè, Anna Rita Bonfigli _, Antonio Domenico Procopio and Fabiola Olivieri

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:93338-93348. https://doi.org/10.18632/oncotarget.21848

Metrics: PDF 1882 views  |   HTML 3079 views  |   ?  


Liana Spazzafumo1,*, Emanuela Mensà2,*, Giulia Matacchione2,*, Tiziana Galeazzi3, Lucia Zampini3, Rina Recchioni4, Fiorella Marcheselli4, Francesco Prattichizzo5, Roberto Testa6, Roberto Antonicelli7, Paolo Garagnani8,9, Massimo Boemi10, Massimiliano Bonafè8, Anna Rita Bonfigli11, Antonio Domenico Procopio2,4 and Fabiola Olivieri2,4

1 Center of Biostatics, INRCA-IRCCS National Institute, Ancona, Italy

2 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy

3 Pediatric Division, Department of Clinical Sciences, Università Politecnica delle Marche, Ospedali Riuniti, Presidio Salesi, Ancona, Italy

4 Center of Clinical Pathology and Innovative Therapy, INRCA-IRCCS National Institute, Ancona, Italy

5 Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni, Italy

6 Clinical Laboratory and Molecular Diagnostics, INRCA-IRCCS National Institute, Ancona, Italy

7 UTIC-Cardiology INRCA-IRCCS, National Institute, Ancona, Italy

8 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy

9 Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden

10 Diabetology Unit, INRCA-IRCCS, National Institute, Ancona, Italy

11 Scientific Direction, INRCA-IRCCS, National Institute, Ancona, Italy

* The authors contributed equally to this work

Correspondence to:

Anna Rita Bonfigli, email:

Keywords: cellular senescence; beta galactosidase activity; type 2 diabetes; aging; inflammaging; Gerotarget

Received: August 02, 2017 Accepted: October 04, 2017 Published: October 16, 2017


β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if “age” could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment.

A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects.

β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normo- and hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition.

Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21848